First-in-human, phase I dose-escalation study of investigational drug MLN9708, a second-generation proteasome inhibitor, in advanced nonhematologic malignancies.

3071 Background: The investigational drug MLN9708 has shown antitumor efficacy in a wide range of tumor xenografts. It dissociates from the proteasome faster and has greater tissue penetration than...